Enlivex Therapeutics Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Oren Hershkovitz
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 5yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 5yrs |
| Promedio de permanencia en la Junta Directiva | 2yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Sep 13
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
Apr 04Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Dec 13Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Jul 25Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Apr 05Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Nov 16Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Sep 30Enlivex to gets US patent covering use of cell therapy Allocetra
Sep 06Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Aug 29Envilex Therapeutics reports Q2 results
Aug 22We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Jul 08Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment
Jul 06We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Mar 23Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Nov 25We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Aug 12Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy
Jun 15Enlivex issued new Canadian patent for Allocetra immunotherapy
Jun 01We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn
Apr 29Enlivex shares rise 20% on positive Allocetra data in COVID-19
Feb 03Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Jan 11
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?
Nov 19Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$22m |
| Mar 31 2024 | n/a | n/a | -US$26m |
| Dec 31 2023 | n/a | n/a | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | n/a | n/a | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | n/a | n/a | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | n/a | n/a | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$296k | US$38k | -US$10m |
Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Oren es razonable en comparación con empresas de tamaño similar en el mercado US.
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Oren con los resultados de la empresa.
CEO
Oren Hershkovitz (47 yo)
5yrs
Permanencia
US$295,600
Compensación
Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 10.8yrs | US$536.00k | 3.62% $ 828.2k | |
| Chief Executive Officer | 5yrs | US$295.60k | 0.12% $ 27.3k | |
| Chief Financial Officer | 8.8yrs | US$132.00k | 0.0088% $ 2.0k | |
| Senior Director of Operations | 2.8yrs | sin datos | sin datos | |
| Director of HR | 2.8yrs | sin datos | sin datos |
5.0yrs
Permanencia media
47yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ENLV es experimentado (5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 10.8yrs | US$536.00k | 3.62% $ 828.2k | |
| Independent Director | 1.6yrs | sin datos | sin datos | |
| Independent Director | 10.8yrs | sin datos | 0.85% $ 193.9k | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Independent Vice Chairman of the Board | 2.5yrs | sin datos | 0% $ 0 | |
| Director | 3.9yrs | sin datos | 0.013% $ 2.9k | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Clinical Advisor | less than a year | sin datos | sin datos | |
| Clinical Advisor | less than a year | sin datos | sin datos | |
| Independent Director | 10.8yrs | sin datos | 0.024% $ 5.4k | |
| Clinical Advisor | less than a year | sin datos | sin datos | |
| Clinical Advisor | less than a year | sin datos | sin datos |
2.0yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de ENLV no se considera experimentada (2 años de permanencia promedio), lo que sugiere una nueva junta directiva.